Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay cystic fibrosis treatment saw revenue growth while new drugs’ performances ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Dr. Vinay Prasad, who oversees FDA’s vaccine and biologics center, resigned in July after coming under fire from conservative ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

These healthcare stocks are making strides in very important ways. The healthcare industry revolves around constant innovation in areas like biotechnology, pharmaceuticals, medical devices, and ...

Krystal Biotech Inc. advanced stock charts by Barron's. View KRYS historical stock data and compare to other stocks, and exchanges.

Vertex Pharmaceuticals (VRTX) is rapidly closing the market capitalization gap with pharmaceutical behemoth Pfizer (PFE), leveraging a robust growth trajectory and a diversified pipeline that ...

Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC ...

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.

Kilroy Realty Corporation has locked in another life sciences tenant for its Oyster Point project in South San Francisco. San ...